These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26562503)

  • 1. PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
    Hansen AR; Siu LL
    JAMA Oncol; 2016 Jan; 2(1):15-6. PubMed ID: 26562503
    [No Abstract]   [Full Text] [Related]  

  • 2. PD-L1 expression as a potential predictive biomarker.
    Fusi A; Festino L; Botti G; Masucci G; Melero I; Lorigan P; Ascierto PA
    Lancet Oncol; 2015 Oct; 16(13):1285-7. PubMed ID: 26433815
    [No Abstract]   [Full Text] [Related]  

  • 3. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
    Farwell MD; Clark AS; Mankoff DA
    JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
    [No Abstract]   [Full Text] [Related]  

  • 4. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
    Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
    Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
    Jørgensen JT
    Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 inhibition with MPDL3280A for solid tumors.
    Cha E; Wallin J; Kowanetz M
    Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Dec; 139(12):1477-8. PubMed ID: 26619015
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-L1 antibody active in metastatic bladder cancer.
    Brower V
    Lancet Oncol; 2015 Jan; 16(1):e11. PubMed ID: 25638546
    [No Abstract]   [Full Text] [Related]  

  • 10. Is PD-L1 Expression a Biomarker of Response?
    Colwell J
    Cancer Discov; 2015 Dec; 5(12):1232. PubMed ID: 26516064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer Immunotherapy and challenges for the Pathologist: state of the art.
    Callea M; Pedica F; Doglioni C
    Pathologica; 2016 Jun; 108(2):48-58. PubMed ID: 28195250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone.
    Afreen S; Dermime S
    Hematol Oncol Stem Cell Ther; 2014 Mar; 7(1):1-17. PubMed ID: 24398144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
    Joo MK; Park JJ; Chun HJ
    World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The science of checkpoint inhibition in kidney cancer.
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):214-7. PubMed ID: 27166601
    [No Abstract]   [Full Text] [Related]  

  • 16. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
    Shin DS; Ribas A
    Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
    Chen DS; Irving BA; Hodi FS
    Clin Cancer Res; 2012 Dec; 18(24):6580-7. PubMed ID: 23087408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Companion diagnostics for the targeted therapy of gastric cancer.
    Yoo C; Park YS
    World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.